Ribavirin – razlika između verzija

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
Interaktivna pretraga historije
← Starija izmjenaNovija izmjena →
Uklonjeni sadržaj Dodani sadržaj
VizualnoWikitekst
Dcirovicbot (razgovor | doprinos)
Botovi
12.945.688 izmena
m .
Dcirovicbot (razgovor | doprinos)
Botovi
12.945.688 izmena
m .
Red 80: Red 80:
| sec_combustion =
| sec_combustion =
}}
}}
'''Ribavirin''' je [[organsko jedinjenje]], koje sadrži 8 [[atom]]a [[ugljenik]]a i ima [[Molekulska masa|molekulsku masu]] od 244,205 [[Јединица атомске масе|Da]].<ref>Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005 Oct;68(1):10-7. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/16087250 16087250]</ref><ref>Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK: Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(50): 705-6. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/4340949 4340949]</ref><ref>Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006 Oct;13(10):683-9. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/16970600 16970600]</ref><ref>Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C: Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/16123681 16123681]</ref><ref>{{Cite pmid|21059682|noedit}}</ref><ref>{{cite pmid|18048412|noedit}}</ref>
'''Ribavirin''' je [[organsko jedinjenje]], koje sadrži 8 [[atom]]a [[ugljenik]]a i ima [[Molekulska masa|molekulsku masu]] od 244,205 [[Jedinica atomske mase|Da]].<ref>Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005 Oct;68(1):10-7. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/16087250 16087250]</ref><ref>Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK: Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(50): 705-6. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/4340949 4340949]</ref><ref>Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006 Oct;13(10):683-9. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/16970600 16970600]</ref><ref>Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C: Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. [[PubMed|PMID]] [http://www.ncbi.nlm.nih.gov/pubmed/16123681 16123681]</ref><ref>{{Cite pmid|21059682|noedit}}</ref><ref>{{cite pmid|18048412|noedit}}</ref>
== Osobine ==
== Osobine ==


Verzija na datum 15 april 2014 u 03:50

Ribavirin
Klinički podaci
Robne marke Copegus, Rebetol, Rebetron, Rebretron
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 36791-04-5
ATC kod J05AB04
PubChem[1][2] 37542
DrugBank DB00811
ChemSpider[3] 34439
ChEMBL[4] CHEMBL1643 DaY
Hemijski podaci
Formula C8H12N4O5 
Mol. masa 244,205
SMILES eMolekuli & PubHem
Fizički podaci
Tačka topljenja 174-176 °C (-111 °F)
Farmakokinetički podaci
Poluvreme eliminacije 9,5 h
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Respiratorno (inhalacija)

Ribavirin je organsko jedinjenje, koje sadrži 8 atoma ugljenika i ima molekulsku masu od 244,205 Da.[5][6][7][8][9][10]

Osobine

Osobina Vrednost
Broj akceptora vodonika 7
Broj donora vodonika 4
Broj rotacionih veza 3
Particioni koeficijent[11] (ALogP) -2,7
Rastvorljivost[12] (logS, log(mol/L)) -0,3
Polarna površina[13] (PSA, Å2) 143,7

Reference

  1. ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. ↑ Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005 Oct;68(1):10-7. PMID 16087250
  6. ↑ Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK: Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(50): 705-6. PMID 4340949
  7. ↑ Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006 Oct;13(10):683-9. PMID 16970600
  8. ↑ Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C: Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. PMID 16123681
  9. ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. DOI:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682. 
  10. ↑ David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. DOI:10.1093/nar/gkm958. PMC 2238889. PMID 18048412. 
  11. ↑ Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A 102: 3762-3772. DOI:10.1021/jp980230o. 
  12. ↑ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488-1493. DOI:10.1021/ci000392t. PMID 11749573. 
  13. ↑ Ertl P., Rohde B., Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714-3717. DOI:10.1021/jm000942e. PMID 11020286. 

Literatura

Spoljašnje veze

Portal Medicina
Portal Hemija

Šablon:Medicinsko upozorenje-lat

Izvor: https://sh.wikipedia.org/w/index.php?title=Ribavirin&oldid=3913660